Cardiac involvement in sarcoidosis: Evolving concepts in diagnosis and treatment

Joseph P Lynch III1*, Michael C Fishbein2, Jason S Bradfield3 and John A Belperio1

1The Division of Pulmonary and Critical Care Medicine, Clinical Immunology, Allergy and Sleep, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
2Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
3Division of Cardiology, UCLA Cardiac Arrhythmia Center, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Abstract

Clinically evident cardiac involvement has been noted in at least 2 to 7% of patients with sarcoidosis, but occult involvement is much higher (> 20%). Cardiac Sarcoidosis (CS) is often not recognized as an antemortem, as sudden death may be the presenting feature. Cardiac involvement may occur at any point during the course of sarcoidosis and may occur in the absence of pulmonary or systemic involvement. Sarcoidosis can involve any part of the heart. The prognosis of CS is related to the extent and site(s) of involvement. Most deaths due to CS are due to arrhythmias or conduction defects, but granulomatous infiltration of the myocardium may cause progressive and ultimately lethal cardiomyopathy. The definitive diagnosis of isolated CS is difficult and the yield of Endomyocardial Biopsies (EMB) is low. Treatment of CS is often warranted even in the absence of histologic proof. Radionuclide scans are integral to the diagnosis. Gadolinium-enhanced cardiac magnetic imaging scans and 18Fluorodeoxyglucose (18FDG)-Positron Emission Tomography (PET) are the key imaging modalities to diagnose CS. The prognosis of CS is variable, but mortality rates of untreated CS are high. Randomized therapeutic trials have not been done, but corticosteroids (alone or combined with additional immunosuppressive agents) are the mainstay of therapy. Additionally, anti-arrhythmic agents and therapy for heart failure are often required. Because of the potential for sudden cardiac death, an Implantable Cardioverter-Defibrillator (ICD) should be placed in any patient with CS and serious ventricular arrhythmias or heart block and should be considered for cardiomyopathy. Cardiac transplantation is a viable option for patients with end-stage CS refractory to medical therapy.

Abbreviations

Introduction

In 2017 we reviewed Cardiac Sarcoidosis (CS) in-depth [1] but many studies since that publication have refined the role of radionuclide diagnostic techniques and provided additional therapeutic approaches for CS. Nonetheless, optimal management (diagnosis and therapy) remains controversial. In this review, we first describe multiple sentinel studies in the 1970s through 2000s and update recent findings and advances in the field.

Clinically evident sarcoidosis involving the heart has been noted in at least 2 to 7% of patients with sarcoidosis [2–5] but occult involvement is much higher (> 20%) [1,6,7]. Sudden Cardiac Death (SCD) may be the presenting feature of CS [8–14] and may occur in the absence of extra-cardiac involvement [15,16]. Corticosteroids (steroids) have been the mainstay of therapy for CS for more than 50 years [13,17–22], but randomized, placebo-controlled trials have not been done, in large part due to the rarity of CS and potential for severe adverse outcomes (including death) in untreated patients [9,13]. As will be discussed in detail later, steroids have been associated with favorable responses in large retrospective trials of CS [23–25] but failures or relapses have led to the use of Immunosuppressive Agents (IA) [26], usually in addition to steroids [27–29]. Further, given the possible role of tumor necrosis factor-α (TNF-α) in the pathogenesis of sarcoidosis [30], TNF-α antagonists have been used to treat CS, usually in cases failing steroids or other IA [31–34]. However, data regarding the use of TNF-α antagonists are even more limited than steroids or IA. Given the lack of randomized trials, optimal therapy of CS is controversial. Additionally, the optimal staging of therapy has not been clarified, as diagnostic modalities (principally radionuclide scans) have changed within the past several years. Currently, Positron Emission Tomography (PET) [35–39] and magnetic resonance imaging (MRI) [40–42] are considered the most useful and specific imaging techniques to diagnose and follow CS, but data are limited. Radionuclide techniques are exceptionally expensive and indications for their use, and appropriate guidelines to follow the course of CS have not been established. In this manuscript, we address all of these issues, even though the optimal approach remains to be determined.

Incidence of cardiac involvement in sarcoidosis

The incidence of cardiac involvement in sarcoidosis (both cardiac and non-cardiac) are markedly different according to racial, ethnic, gender, age, and geographic factors and may vary over time [43]. Sarcoidosis (both cardiac and extra-cardiac) is more common in Blacks [44] and has a higher mortality rate in Blacks than Caucasians [45]. Sarcoidosis is much more common in northern European countries (particularly Scandinavia) and the British Isles and Ireland, but is rare in southern Europe, Central, and South America, Israel, and East Asia [43]. Estimated incidence rates (per 100,000) of sarcoidosis have been reported as follows: USA (17.8, African Americans); 8.1 (whites); 4.3 (Hispanics); 3.2 (Asians) [46]; Sweden 21.7 (women); 16.5 (men) [47]; Finland (11.4) [43]; Denmark (6.4–8.4) [48]; United Kingdom and Ireland (5.0) [49]; Spain (0.4) [50]; Poland (5.0) and Hungary (3.4) [43]; South Korea (3.4) [51]; Israel (0.8) [52]; Korea (0.03–0.125) [53]; Singapore (0.56) [54], Japan (1.01) [55].

Compared to other ethnicities, the incidence of CS is much higher in Japanese individuals with sarcoidosis and is associated with a higher mortality [13,18,56–58]. In Japan, cardiac involvement is the leading cause of death due to sarcoidosis, accounting for 77 to 85% of deaths [13,59]. By contrast, in the United States, 13 to 50% of sarcoid deaths have been attributed to cardiac involvement [8,60].

Several necropsy series in the USA and United Kingdom (UK) cited pathological evidence for cardiac involvement in 19.5% to 28% of patients with sarcoidosis [9,10,61–63].

Genetics of cardiac sarcoidosis

The increased frequency of cardiac involvement in Japanese patients with sarcoidosis strongly suggests genetic influence [57,58,64,65], but the specific genes responsible for sarcoidosis have not been elucidated [64]. The genetics of sarcoidosis (cardiac and non-cardiac) are exceptionally complex [66] and are beyond the scope of this manuscript.

Pathology and sites of involvement

In the 1970s, the salient pathological and clinical features of CS were outlined in sentinel publications [9,10,13]. An expert pathologist is important to recognize key findings attributable to sarcoidosis versus other similar disorders. Grossly, the heart in CS will show scars in unusual locations with normal coronary arteries, indicating that the lesions are not ischemia-related healed myocardial infarcts [9,10]. The hallmark of sarcoidosis, granulomatous inflammation, may involve any part of the heart [9,10,67]. Non-Necrotizing Granulomas (NNG) composed of epithelioid histiocytes, with multinucleated giant cells containing Schaumann bodies or asteroid bodies, lymphocytic infiltration, and patchy fibrosis may be observed [1,9,10,12,27,67] (Figure 1A–E). The myocardium is most frequently involved in CS; pericardial and endocardial involvement usually reflect extensions of myocardial disease [9,10,16,68]. Areas of involvement in descending order of frequency are the left ventricular free wall, Interventricular Septum (IVS), papillary muscles, Right Ventricle (RV), and atria [9,16].

Prognosis of cardiac sarcoidosis

Cardiac involvement may occur at any point during the course of sarcoidosis and may occur in the absence of pulmonary or systemic involvement [13,15,16]. In 1977,
Conduction disturbances and arrhythmias are the most common cardiac manifestations of sarcoidosis and reflect granulomatous infiltration within the conduction system [e.g., Sinoatrial (SA) node, Atrioventricular (AV) node, Bundle of His] or ventricular walls [1,9]. AV Block (AVB) [70] is the most common arrhythmic manifestation of CS (26–67%) [71], but Bundle Branch Block (BBB), nonspecific interventricular conduction delay, Premature Ventricular Contractions (PVCs), Ventricular Tachycardia (VT), and other arrhythmias may occur [9,72,73]. A prospective study in Ottawa, Canada evaluated 32 adults < 60 years old (2010–2013) with unexplained 2nd or 3rd degree AVB and no previous history of sarcoidosis in any organ [74]. 18Fluorodeoxyglucose (18FDG) Positron Emission Tomography (PET) scans were consistent with CS in 11 (34%); extra-cardiac sarcoidosis was subsequently confirmed in all 11 cases. During an average follow-up of 21 +/- 9 months, Adverse Cardiac Events (ACE) were documented in three: HF (n=3); VT (n = 2) [74]. In the series reported by Roberts, et al. in the USA, Electrocardiograms (ECGs) demonstrated PVCs (29%), present in 16 patients; ventricular aneurysms were identified in eight patients. Recurrent pericardial effusions were fatal in three patients [9]. In 1978, Silverman, et al. reviewed 84 consecutive necropsies from patients with sarcoidosis seen at Johns Hopkins Hospital (USA) from 1899–1977; 23 patients (27%) had granulomatous cardiac involvement [10]. Among four patients with widespread cardiac lesions, three had arrhythmias and sudden unexpected death. Of the 19 patients with microscopic myocardial granulomas, only four had symptoms attributed to CS [10]. In 1981, Fleming and Bailey reported a cohort of 197 patients with CS in the United Kingdom (UK); sudden death occurred in 48 (24%) and was the presenting symptom in 34, (17%) [17]. In 2001, Yazaki, et al. reported 95 Japanese patients with CS seen between 1984, and 1996; 40 died from cardiac causes during follow-up Heart Failure (HF) in 29; sudden death in 11 [18]. Overall survival rates were 85% at 1 year, 60% at 5 years, and 44% at 10 years. Three parameters were independent predictors of mortality by multivariate analysis: 1) New York Heart Association functional class [Hazard Ratio (HR) 7.7 per class increase, p = 0.0008]; 2) left ventricular end-diastolic diameter [HR 2.6 per 10 mm increase, p = 0.02]; 3) Sustained Ventricular Tachycardia (SVT) [HR 7.2, p = 0.03] [18].

While CS is often clinically silent for months or even years, attributable mortality rates of up to 50–85% in necropsy series of CS have been cited [13,14,63,69]. In one necropsy series in the USA, 10 of 25 deaths attributed to CS had no extra-cardiac disease [16]. Hu, et al. reviewed necropsies from 44 cases with sarcoidosis seen at the Mayo Clinic over 20 years (1994–2013) [14]. Sarcoiodosis was not diagnosed antemortem in 16 (36%). Overall, 15 deaths were due to sarcoidosis (7 due to CS) [14]. Most deaths due to CS are due to VA or conduction defects; HF due to massive granulomatous infiltration of the myocardium accounts for at least 25% of deaths [1,9,10,13,18]. Radionuclide imaging studies to identify active sites of granulomatous inflammation are critical as early treatment may avert the potentially lethal progression of the cardiac lesion(s).
Involvement of cardiac valves

Severe involvement of cardiac valves is rare (< 3%) [9,10,19], but valvular dysfunction may result from sarcoid involvement of the papillary muscles [9,83]. Severe granulomatous infiltration mandating mitral valve replacement has been described [19,84]. Less commonly, the tricuspid, aortic, or pulmonary valves are involved [9].

Pericardial involvement

Infiltration of the pericardium may lead to pericardial effusion(s) [9,85–88] and, rarely, constrictive pericarditis [89]. In most patients with pericardial involvement, myocardial involvement is also present [9]. In one study, 13 of 14 sarcoidosis patients with pericardial effusions had abnormal 99technetium ( 99Tc)-pyrophosphate scans, consistent with infiltrative cardiomyopathy [88].

Cardiac vascular involvement

Coronary arteries are typically normal in patients with CS. Myocardial scars in the absence of coronary disease is typical of CS [9,10]. Coronary arterial aneurysms [90], coronary artery spasm [91], acute coronary syndrome, [92] and coronary artery vasculitis [93] have been described in CS, but are exceptionally rare.

Involvement of other organs

Extra-cardiac involvement is usually present in patients with CS [4], but symptoms may be absent until the initial presentation with Sudden Cardiac Death (SCD) [9,16]. In the necropsy series of 35 cases of CS from the NHLBI (USA), 26 patients died of arrhythmias or conduction disturbances [9]. In this subset, 25 (96%) had lymph node involvement; 20 (77%) had lung involvement; 17 (68%) had hepatic granulomas. In a British study of 20 necropsies in patients with CS, other sites of organ involvement included: lungs in 19 (95%); lymph nodes 19 (95%); spleen, 7 (35%); liver, 7 (35%) [61]. Among 95 Japanese patients with CS, extra-cardiac involvement included: lungs in 56 patients (59%); heart in 39 (41%); skin in 16 (16%) [18]. In a French study of 41 patients with CS, extra–cardiac involvement was present in all cases [27]. In 63% of cases, cardiac involvement developed during follow-up of extra-cardiac sarcoidosis [27]. In a series of 73 cases of CS seen at the University of Cincinnati (USA) over 6 years, all had extra–cardiac involvement [most commonly lung (94.5%)] [4]. A study from Western Australia reported 52 cases of CS; 91% had lung involvement; the mean number of extra–cardiac sites was 2.2 [94]. Given the high incidence of extra–cardiac involvement in patients with CS, biopsies of lung, mediastinal or hilar lymph nodes, liver, or skin are indicated when clinical features, radiographic techniques (HRCT scan or PET), or magnetic resonance imaging indicate probable involvement at those sites [95–97]. Examination by an expert ophthalmologist is reasonable to determine if ocular involvement (principally uveitis) is present [97]. However, blind biopsies in the absence of specific radiographic or clinical findings are not appropriate due to low yield.

Isolated cardiac sarcoidosis

Isolated CS is uncommon, but some studies cited a lack of extra–cardiac involvement [16,98]. In a necropsy study in the USA, 12 of 25 (40%) patients who died as a result of CS had no signs of extra–cardiac involvement [16]. In a retrospective study from Finland, 33 of 52 (66%) patients with CS seen between 2000–2010 had disease isolated to the heart [98]. In a more recent study from Finland, 351 cases of CS were reported
from 1998–2015, although an antemortem diagnosis was made in only 262 cases [99]. High–grade AVB was the most common first sign of CS (42%), followed by HF (17%), unexpected SCD or aborted SCD (14%), and sustained VT (14%). Of all deaths until the end of 2015, 54/84 (64%) were unexpected SCD due to CS that was clinically silent during life or defied all attempts at diagnosis [99]. Kaplan Meier's estimate of survival was 85% at 5-years and 76% at 10 years [99].

**Diagnosis of cardiac sarcoidosis**

The definitive diagnosis of isolated CS is difficult. The yield of Endomyocardial Biopsies (EMB) is low and clinicians often rely on non-invasive imaging to diagnose and follow CS. Treatment of CS is often warranted even in the absence of histologic proof. Guidelines to diagnose CS were developed in 1993 by the Japanese Ministry of Health and Welfare [100] and in 1999 by the research group in the USA conducting the ACCESS study [101]. In 2014, an international consensus statement regarding diagnosis and management of CS was written by experts chosen by the Heart Rhythm Society in collaboration with representatives from the American College of Cardiology (ACC), American Heart Association (AHA), American College of Chest Physicians (ACCP), the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG), and other societies [102]. Given the potential mortality associated with CS, early diagnosis and treatment is critical and may be life-saving. Serum Angiotensin Converting Enzyme (SACE) levels are insensitive for CS [103]. The presence of abnormal ECG or HF is a nonspecific feature. Techniques to diagnose CS have evolved over the past 3 decades. Gadolinium (Gd)–enhanced cardiac magnetic resonance imaging (Gd–CMR) [104] and 18FDG–PET [105,106] are the best tests to determine the presence and extent of cardiac involvement (discussed in detail later).

**Electrocardiogram**

A resting ECG is recommended by WASOG and the American Thoracic Society (ATS) as an appropriate screening test in all patients with sarcoidosis [107]. Abnormalities on ECG (e.g., conduction disturbances, arrhythmias, or nonspecific ST and T-wave changes) have been noted in 20 to 31% of sarcoid patients [7,10,108–110]. In one necropsy study, 42% of sarcoid patients with mild cardiac involvement (microscopically evident granulomas) and 75% of patients with severe involvement (gross evidence of cardiac granulomas or infiltration at necropsy) had arrhythmias or conduction disturbances [10]. However, a large cohort of Caucasian Scandinavians (Swedes) (n = 1,017) was retrospectively screened for CS at disease onset with ECG and the presence or absence of cardiac-related symptoms [110]. Abnormalities on ECG were present in 166 (16.3%) and CS was diagnosed later in 22 (13.2%) in this group. In sharp contrast, CS developed in only one of 801 (0.1%) patients with a normal ECG. The risk for CS was higher in patients with an abnormal ECG combined with cardiac symptoms [11/40 (27.5%)] compared to abnormal ECG without cardiac symptoms [11/126 (8.7%), p < 0.01]. Further, patients with Lofgren's syndrome (LS) had a reduced risk of CS compared to those without LS (p < 0.05) [110].

This suggests an extraordinarily low risk of CS in the presence of a normal ECG in this homogeneous population, but may not necessarily apply to other ethnicities (e.g., Blacks or Japanese). Nonetheless, resting ECGs are insensitive for detecting cardiac involvement. Further, the clinical significance of nonspecific ECG abnormalities is unclear. Polish investigators assessed risk for CS in a cohort of 201 Caucasians with sarcoidosis seen between 2012–2015 [111]. CMR was consistent with CS in 49 (24.4%). The univariate analysis cited the following factors associated with increased risk of CS (p < 0.01 in all): male sex (OR 2.5); cardiac–related symptoms (OR 3.53); extra–thoracic sarcoidosis (OR 3.48); elevated serum pro–N–terminus brain natriuretic protein (pro–NT–BNP) (OR 3.82); any abnormality on ECG (OR 5.38); contemporary radiographic progression of sarcoidosis in lungs (OR 2.98). Abnormalities on transthoracic echocardiogram (TTE) and Holter ECG were also risk factors, but not significant in multivariate analysis [111]. Elevated pro–NT–BNP coupled with abnormal ECG was associated with the specificity of 93%, a higher specificity than Holter or exercise tests [111], and may be a cost effective way to assess the risk of CS in patients with an abnormal ECG.

**Transthoracic Echocardiography (TTE)**

Transthoracic echocardiography is nonspecific but is invaluable to assess cardiac chamber(s) size and function in patients with suspected or confirmed CS [7,68]. In early studies, abnormalities on TTE were detected in 14% to 41% of patients with sarcoidosis, even in the absence of ECG abnormalities and clinical symptoms [6,7]. Salient abnormalities include global or focal hypokinesia or dyskinesia; wall motion abnormalities; chamber enlargement; ventricular wall thickening or aneurysms; ventricular dilatation or hypertrophy; depressed Ejection Fraction (EF); diastolic dysfunction; valvular regurgitation; papillary muscle dysfunction; pericardial effusions [1,112]. In some cases, macroscopic areas of bright echoes were noted, reflecting granulomatous inflammation [113], described as a “speckled or snowstorm pattern” [62]. Wall thinning or thickening of the IVS localized to the basal portion is characteristic of CS [68,113,114]. Yazaki, et al. reported TTE findings from 15 patients with CS and 30 patients with idiopathic dilated cardiomyopathy (IDC) [68]. Thinning (< 7 mm) or thickening (> 13 mm) of the ventricular wall (typically in the IVS) were noted in 11 of 15 (73%) patients with CS. ECG demonstrated HB in all 11 patients. By contrast, only 17% of patients with IDC had abnormal wall thickness. Interestingly, 201thallium scans, performed in 14 patients with CS in that study, revealed perfusion defects in 13 (93%) [68]. Echocardiography alone is not sensitive to detect early myocardial sarcoid lesions [3,7] but is noninvasive and a relatively inexpensive way to assess and follow cardiac size and function.

Two-Dimensional Speckle-Tracking (2D–ST) echocardiography is more sensitive than conventional TTE for detecting early CS in patients with normal or mild cardiac dysfunction [115–118]. However, since 2D–ST is rarely performed in most medical centers, we will not further discuss this technique.
Radionuclide scans

Radionuclide scans are integral to the diagnosis of CS. Beginning in the 1970s and 1980s, gallium67 (Ga67)-citrate [103,119] and thallium201 (Tl201) scans [6,103,119,120] were used to diagnose and follow CS. In sentinel studies, Tl201 scans were superior to TTE to diagnose CS [6,103,120,121]. Tellier, et al. described a phenomenon of “reverse distribution” in CS [120]. Perfusion defects were present on Tl201 scans at rest in 16 patients with CS; the perfusion defects improved or completely resolved in 13 of 16 patients with exercise or dipyridamole [120]. Other studies affirmed that perfusion defects noted at rest in CS disappeared or decreased in size following exercise or infusions of dipyridamole or adenosine [6,122]. This differs from coronary artery disease, in which defects at rest worsen or fail to improve with exercise, dipyridamole, or adenosine [6,123]. The above studies are useful primarily for historical interest as these radionuclide techniques have been supplanted by 18FDG-PET [104,124] and Gd-enhanced CMR [124,125] to diagnose and/or monitor CS.

Positron emission tomography (PET)

18FDG-PET has been used to diagnose and “stage” sarcoidosis in thoracic and extra-thoracic sites [126–128], including CS [94,124,127,129,130] (Figures 2–6). Increased update of 18FDG occurs within activated leukocytes, macrophages, and CD4+ T lymphocytes, major components of granulomas [128], and correlates with inflammation in the lung or extra-pulmonary sites [126,127]. 18FDG-PET is a sensitive marker of disease activity in sarcoidosis [129,131] and is superior to Ga67-citrate [132] and Tl201-scans [133] to diagnose CS. The specificity of PET

Figure 2: Patient with nonischemic cardiomyopathy and VT with mismatch. Perfusion shows normal septal update with decreased lateral uptake by NH3. On FDG, the myocardial uptake is increased on the lateral wall, which indicates inflammation. Reproduced with permission from Semin Respir Crit Care Med, 2017, Sayah, et al. (Sayah, 2017, Vol. 38, Pages 477-498).

Figure 3: Patient referred for VT ablation with presumed ARVD with right precordial T wave inversion. PET scan demonstrated 18FDG uptake in right hilar lymph node and patchy focal uptake throughout both ventricles. Biopsy of the hilar node revealed non-necrotizing granulomas (NNG) consistent with sarcoidosis. Reproduced with permission from Semin Respir Crit Care Med, 2017, Sayah, et al. (Sayah, 2017, Vol. 38, Pages 477-498).
as a diagnostic tool in CS relies on the suppression of normal myocyte uptake of glucose. For this reason, prolonged fasting (> 12 hours) and fatty acid loading [134,135] are required before imaging to suppress myocardial glucose metabolism in favor of oxidation of free fatty acids [136]. PET scans in CS may show different patterns of diffuse and focal uptake (Figure 2) [137]. Three basic patterns in CS have been observed: diffuse, focal, and focal on diffuse; perfusion abnormalities may also be present [102] (Figures 4-6). In an early study in Japan, 17 cases of CS had FDG-PET, TI201, and Ga67 scans [133]. FDG-uptake in the heart was increased in 14/17 (82%) whereas abnormal myocardial uptake was noted in only six (35%) and three (18%) cases on TI201 or Ga67 scans, respectively. FDG-PET scans were repeated in seven patients after one month of steroid therapy; FDG defects disappeared entirely in five and improved in two [133]. In 2012, a meta-analysis of all studies relevant to FDG-PET to diagnose CS reported pooled sensitivities and specificities of 89% and 78%, respectively [105].

Focal perfusion defects and FDG uptake on PET in patients with suspected CS assess the presence or absence of inflammation [35,36,134]. Early in the course of CS, PET may show focal FDG uptake at sites of granulomatous inflammation without associated perfusion defects [35]. In later stages, after the inflammation has “burned out”, perfusion defects may persist whereas FDG uptake resolves [35]. Serial PET scans have been used to evaluate response to therapy in CS and prognosis [36-38,133,138] but randomized trials are lacking. Reduction in FDG uptake has been noted following therapy with steroids and has been associated with improved prognosis [37,133,139]. Serial PET scans were performed in 16 patients with CS before and during treatment [36]. Quantitative assessment of FDG-avid cardiac lesions was interpreted via four PET parameters; the clinical response was evaluated by symptoms and clinical criteria. Quantitative PET parameters significantly declined (inflammation improved) on repeat PET in patients who clinically were stable or improved whereas those whose PET had not improved were clinically worse [36]. Shelke, et al. evaluated 15 patients with CS who had PET scans before and after initiation of steroid therapy (126 +/- 54 days post) [37]. Four cases were considered non-responders [defined as lack of improvement or worsening in clinical outcomes (i.e., VA, HF, LV systolic function) despite steroid therapy]. Myocardial maximum standardized uptake of FDG (SUV max) declined (improved) significantly in 11 patients responding to steroids (p < 0.004) but increased in non-responders (p < 0.05) on follow-up. Further, the number of LV segments with FDG uptake declined significantly in responders (p = 0.007) but trended towards increase in non-responders (p = 0.465). Importantly, heterogeneous uptake on baseline PET and increase in intensity and area of myocardial involvement on follow-up were associated with poor clinical outcomes despite steroid therapy [37]. In another study of 118 cases with known or suspected CS, FDG-PET scans were abnormal in 71 (60%) [134]. Over a median follow-up of 1.5 years, Adverse Cardiac Events (ACE) occurred in 31 (26%) and included 27 episodes of VT and 8 deaths. Cardiac PET findings were predictive of ACE; the presence of both a perfusion defect and abnormal FDG uptake (29% of patients) was associated with an HR of 3.9 (p < 0.01) for ACE and remained significant after adjusting for LVEF and clinical criteria [134]. Serial FDG-PET scans were done in 34 pts with CS (mean of 4 per patient during 2.3 years of follow-up) at Stanford (USA) from 2010 to 2017 [38]. Presenting symptoms included advanced HB [n = 12 (35%), HF [n =12 (35%), and VA [n = 14 (41%)]. At baseline, PET showed increased cardiac FDG uptake in 27/34 (79%),

Figure 4: Multiphase inflammation in a 49-year old female with a history of heart block requiring a pacemaker. She was found to have nonsustained VT on pacer interrogation. PET scan revealed decreased anteroseptal perfusion with focal uptake of FDG in the septum and inferolateral wall. The mismatch in the septum suggests chronic scarring; increased uptake in the inferolateral region suggests active inflammation. Reproduced with permission from Semin Respir Crit Care Med, 2017, Sayah, et al. {Sayah, 2017, Vol. 38, Pages 477-498}.  

consistent with active CS; seven (21%) showed no active CS. The most common pattern was patchy uptake (n=21); four showed patchy on diffuse 18FDG uptake. At a median follow-up of 2.3 years, 25 patients (74%) had received prednisone (pred) and 26 (76%) had been treated with pred + methotrexate (MTX). Nine (26%) received tumor necrosis factor-α (TNF-α)-antagonists after failing pred + MTX. At follow-up, 48% of patients had been weaned from pred completely and 20% were on a low maintenance dose (5 to 10 mg). Overall, two patients (6%) had died (one due to infection) [38].

While 18FDG-PET is a pivotal test in patients with CS for initial diagnosis and follow-up, pitfalls have been noted including 1) physiological uptake of 18FDG in myocardium may be found in healthy subjects; 2) normal myocardium may exhibit increased physiologic uptake on the basal and lateral LV walls; 3) apparent increased uptake of 18FDG in myocardium may reflect diet (i.e. not adhering to a low carbohydrate/high-fat diet for at least 12 hours prior to the test); 4) pulmonary hypertension increases RV and IVS 18FDG update because of the mechanical overload; 5) nonspecific 18FDG uptake may be observed in patients with non-sarcoid dilated cardiomyopathies; 6) interpretation may not be straightforward [3]. Artifactual inhomogeneities in PET may be seen in normal myocardium due to the influence of in-plane resolution and wall thickness [140]. Although 18FDG-PET has assumed an important role to diagnose and follow CA sarcoidosis, many centers combine 18FDG-PET with Gd-CMR to diagnose and follow CS [38,40,42,104,141,142], as these dual procedures may provide complementary information. 18FDG is more sensitive for early phases of inflammation, but Gd-CMR is more specific for later phases of scar formation [143,144]. Unfortunately, PET-CT and CMR are incredibly expensive (often > $10,000 per study in the USA) and may not be covered by insurance.

**Cardiac MRI (CMR)**

CMR may identify regional differences in enhancement between diseased and normal myocardial tissue [145,146]. Gadolinium contrast media distributes rapidly into the extracellular space of the myocardium and is excluded from normal myocardial cells. Late gadolinium enhancement (LGE) is typical of CS [143,146,147]. In the setting of fibrosis, regional enhancement of myocardial scar tissue is present [143]. In CS, CMR may demonstrate diffuse or focal enhancement, particularly in the myocardial wall or subepicardial region, thought to reflect edema associated with inflammation in physiological uptake of 18FDG in myocardium may be found in healthy subjects; 2) normal myocardium may exhibit increased physiologic uptake on the basal and lateral LV walls; 3) apparent increased uptake of 18FDG in myocardium may reflect diet (i.e. not adhering to a low carbohydrate/high-fat diet for at least 12 hours prior to the test); 4) pulmonary hypertension increases RV and IVS 18FDG update because of the mechanical overload; 5) nonspecific 18FDG uptake may be observed in patients with non-sarcoid dilated cardiomyopathies; 6) interpretation may not be straightforward [3]. Artifactual inhomogeneities in PET may be seen in normal myocardium due to the influence of in-plane resolution and wall thickness [140]. Although 18FDG-PET has assumed an important role to diagnose and follow CA sarcoidosis, many centers combine 18FDG-PET with Gd-CMR to diagnose and follow CS [38,40,42,104,141,142], as these dual procedures may provide complementary information. 18FDG is more sensitive for early phases of inflammation, but Gd-CMR is more specific for later phases of scar formation [143,144]. Unfortunately, PET-CT and CMR are incredibly expensive (often > $10,000 per study in the USA) and may not be covered by insurance.

**Cardiac MRI (CMR)**

CMR may identify regional differences in enhancement between diseased and normal myocardial tissue [145,146]. Gadolinium contrast media distributes rapidly into the extracellular space of the myocardium and is excluded from normal myocardial cells. Late gadolinium enhancement (LGE) is typical of CS [143,146,147]. In the setting of fibrosis, regional enhancement of myocardial scar tissue is present [143]. In CS, CMR may demonstrate diffuse or focal enhancement, particularly in the myocardial wall or subepicardial region, thought to reflect edema associated with inflammation in physiological uptake of 18FDG in myocardium may be found in healthy subjects; 2) normal myocardium may exhibit increased physiologic uptake on the basal and lateral LV walls; 3) apparent increased uptake of 18FDG in myocardium may reflect diet (i.e. not adhering to a low carbohydrate/high-fat diet for at least 12 hours prior to the test); 4) pulmonary hypertension increases RV and IVS 18FDG update because of the mechanical overload; 5) nonspecific 18FDG uptake may be observed in patients with non-sarcoid dilated cardiomyopathies; 6) interpretation may not be straightforward [3]. Artifactual inhomogeneities in PET may be seen in normal myocardium due to the influence of in-plane resolution and wall thickness [140]. Although 18FDG-PET has assumed an important role to diagnose and follow CA sarcoidosis, many centers combine 18FDG-PET with Gd-CMR to diagnose and follow CS [38,40,42,104,141,142], as these dual procedures may provide complementary information. 18FDG is more sensitive for early phases of inflammation, but Gd-CMR is more specific for later phases of scar formation [143,144]. Unfortunately, PET-CT and CMR are incredibly expensive (often > $10,000 per study in the USA) and may not be covered by insurance.

addition to myocardial scar [145,146,148] (Figure 6). Early experience with CS showed that CMR was superior to TTE [149–151]. In a sentinel study, 16 patients with suspected CS had CMR; localized enhancement of signal intensity on T1-weighted images was present in the LV in eight patients (50%) indicating interstitial edema or scarring [150]. Two patients with LGE also had thinning of the LV septal wall. After one month of steroid therapy, the high-intensity signals had disappeared, with LGE also had thinning of the LV septal wall. After one month of steroid therapy, the high-intensity signals had markedly diminished in all patients. Importantly, TTE were abnormal in only two patients [150]. In another prospective study, both T1-wos scans and CMR were done in 40 patients with sarcoidosis; CMR was abnormal in all five with CS and 17 of 31 (54%) with multi-organ sarcoidosis but without cardiac symptoms [152]. Localized enhancement of signal intensity on T1-weighted images was present in the LV in eight patients (50%) with CS [149,151]. In a sentinel study, 16 patients with suspected CS had CMR; localized enhancement of signal intensity on T1-weighted images was present in the LV in eight patients (50%) with CS [149,151]. In another prospective study, both T1-wos scans and CMR were done in 40 patients with sarcoidosis; CMR was abnormal in all five with CS and 17 of 31 (54%) with multi-organ sarcoidosis but without cardiac symptoms [152]. Findings included increased intramyocardial signal intensity (n=5), focal or patchy increased signal intensity, with or without myocardial thickening (n=10), focal increased signal only on T2-weighted images (n=2) [152]. In 2005, Smedema, et al. reported 58 patients with biopsy-proven pulmonary sarcoidosis who had both T1-wos scans and CMR; 12 (21%) had CS [147]. CMR revealed myocardial LGE in 19 patients, mostly involving basal and lateral segments. In eight of the 19 patients, T1-wos scintigraphy was normal. The sensitivity and specificity of CMR were 100% (CI, 78–100%) and 78% (CI, 64–89%), respectively [147]. In 2008, Ichinose, et al. reported 40 patients with sarcoidosis; 11 had CS [153]. Myocardial hyper-enhancement was noted in 10 of 11 patients with CS but in none of 29 patients without CS. Myocardial hyper-enhancement was most frequent in the subepicardial and mid-myocardial layers (p < 0.001) [153]. In two studies comprising five patients with CS, LGE was present on CMR, mainly distributed in the mid-to-epi-myocardium [154,155]. In another study, 17 patients with CS had both EMB and CMR; CMR was consistent with CS in 13 of 17 (76%) patients whereas EMB were positive in only six (35%) [156]. Sensitivities and specificities with CMR were 76% and 92%, respectively, compared to 35% and 100%, respectively, with EMB [156]. Multi-contrast LGE on CMR may exhibit improved sensitivity for CS [124]. Additionally, LGE may be a marker of myocardial damage in patients with normal cardiac function [157]. Investigators at the University of Chicago reported a cohort of 152 cases of biopsy-confirmed extra-cardiac sarcoidosis who had normal LVFV (> 50%) and were followed for 651 days (2007-2010) [157]. Foci of myocardial LGE were present in 29 (19%) and were associated with a greater prevalence of abnormal ECG (76% vs 31%, p < 0.001), diastolic dysfunction (67% vs 33%, p = 0.05), reduced RVFV (49% vs 55%, p = 0.012), and NSVT (33% vs 6%) compared to cases with no myocardial LGE [157]. Thus, even small foci of myocardial LGE may identify patients with a myocardial injury who may be at risk for NSVT and ACE. Cheong, et al. performed CMR in 31 patients with confirmed extra-cardiac sarcoidosis but no history of heart disease or cardiac symptoms [158]. Abnormal myocardial CMR (LGE) was evident in 8/31 (29%) that suggested small foci of myocardial injury or fibrosis may put patients at risk for late ACE [158].

Cardiac lesions may appear as patchy or focal hyper-enhancement patterns in the LV free wall, papillary muscles, or IVS [124,139,148]. Numerous studies have shown that CMR achieved sensitivities of 75 to > 95% in CS with specificities of ~ 75–80% [145,147,158,159]. LGE on CMR (possibly reflecting the absence of viable myocytes in a collagenous scar) may serve as a prognostic indicator for the severity of disease [41,42,154,155,160]. Among 61 consecutive patients with CS seen in the Netherlands from 2002 to 2012, 37 had CMR; LGE was present in 26 cases [41]. Compared to patients without LGE, there was a trend to a higher rate of VA (29% vs 0%, p = 0.12) and higher rate of composite clinical endpoint (i.e., VA, HF hospitalization, or cardiovascular death) in those with LGE (41% vs 0%, p < 0.05) [41]. By contrast, in a prospective study in Japan, 61 cases of sarcoidosis without clinical cardiac manifestations had CMR; LGE was present on CMR in eight (13%) [161]. Thinning of the IVS on TTE was an independent predictor of myocardial LGE. Study end-point was a composite of all-cause deaths, symptomatic arrhythmias, or HF necessitating admission. During follow-up of 50 +/- 12 months, there was no significant difference in ACE [161]. In a study of 19 Japanese cases with CS, the total number of affected myocardial segments on CMR correlated with duration of sarcoidosis in cases with onset in extra-cardiac sites (p = 0.005) as well as LV ejection fraction (LVEF) and LV diastolic volume [155]. All patients with LVEF < 30% had both subepicardial and transmural lesions. In Finland, 59 patients with CS had CMR from 2004-2015; the prognostic significance of myocardial LGE and thickness of the basal IVS were analyzed [162]. By April 2015, 23 patients had reached the study endpoint, consisting of a composite of cardiac death (n=3); cardiac transplant (n=1); life-threatening cardiac events (n=19). In univariate analysis, myocardial extent of LGE predicted event-free survival as did scar-like thinning (< 4 mm) of the basal IVS and the RVFV (p < 0.05 for all). In multivariate Cox regression analysis, only the extent of myocardial LGE independently predicted outcome (HR = 2.22 per tertile) [162]. In a later study, these investigators retrospectively reviewed 73 cases of Giant Cell Myocarditis (GCM) and determined that 45 cases had intra- or extra-cardiac granulomas consistent with CS [163]. Patients relocated to CS had less HF at presentation (20% vs 66%, p = 0.017) and better one-year transplant-free survival compared to GCM (82% vs 45%, p = 0.011) [163]. A recent meta-analysis reviewed 19 publications up until 2020 regarding the risk of ACE and SCD in patients with symptomatic CS [164]. Positive LGE-MRI and PET were associated with an 8.60 and 9.07 fold increased risk of VA, respectively, and a 6.82 and 3.41 fold increased risk of major ACE, respectively [164].

In a retrospective study in Boston (USA), 107 consecutive cases referred for possible CS had both CMR and PET [40]. LGE on CMR was present in 91 (85%), suggesting CS; increased ¹⁸FEDG uptake on PET was present in 82 (76%). Among 91 with LGE, 60 (66%) had (+) PET [40]. In the UK, 51 consecutive patients with CS had both PET and CMR [39]. Primary composite endpoints were: death; aborted sudden death; sustained VT; CHB; hospital admission for cardiac indication. Secondary endpoints were: fall in LVEF > 10%; NSVT; other cardiac-related hospitalization. Overall, 33/51 (65%) were diagnosed with CS. Sensitivities of PET and CMR were 0.85 and 0.82, respectively. Over a median of 2.2 years, 18 (35%) experienced ACE. Cardiac RV PET abnormality and myocardial LGE were independent predictors of ACE. The strongest predictor of ACE...
were abnormalities in both PET and CMR [39]. In a prospective study of 61 sarcoidosis patients and 26 healthy volunteers (controls), myocardial LGE was present in 15 sarcoidosis patients but no controls [165]. Additional parameters on CMR (i.e., T1 and T2 mapping) provide additional diagnostic and prognostic information [165-167]. In a sentinel study, CMR were performed in 53 cases of proven extra-cardiac sarcoidosis and 36 healthy controls; 40 patients were followed at a mean interval of 144 +/- 35 days [167]. Eighteen sarcoidosis cases were treated with steroids or IA. Myocardial T1 and T2 mapping were increased in sarcoidosis patients compared to controls, and declined (improved) in treated patients (p < 0.01) but not in untreated patients (p = 0.15) [167]. In a recent prospective study (2017-2019), 43 patients (median age 48 years, range 37-54) with proven extra-cardiac sarcoidosis had both PET and CMR simultaneously (hybrid study) to assess the incidence of CS [42]. The authors noted that myocardial LGE was not specific for inflammation and could represent myocardial fibrosis. Hence, newer quantitative mapping techniques to detect early stages of CS (e.g., native T1 and T2 mapping) were applied. Abnormal T1 mapping correlates with myocardial fibrosis or inflammation while T2 mapping may detect myocardial edema that may occur in the context of myocardial inflammation [42]. Seven patients exhibited diffuse myocardial uptake that was attributed to inadequate dietary preparation and were excluded. In the remaining 36 cases, the following abnormalities were noted on CMR: LGE in 14 (39%); abnormal T1 mapping in 10 (27%); abnormal T2 mapping in two (6%). PET was (+) in 17 (47%). The authors' defined active CS as LGE (+) and (+) PET; chronic CS if CMR (+) but PET (-); no CS if CMR (-) regardless of PET status. Using these criteria, 13 (36%) were considered active CS; 5 (14%) chronic CS; 18 (50%) no CS. Data are complicated by the fact that 44% of cases were on steroid therapy and six were on additional IA at the time of study entry [42]. The authors suggested that simultaneous performance of both CMR and PET may be useful to assess prognosis and potential responsiveness to therapy.

Serial CMR may be valuable to follow the course of CS [150], but few long-term follow-up studies have been done. Until recently, CMR could not be done in patients with pacemakers or ICDs. The development of CMR-compatible pacemakers and pacemaker leads [168] made it possible to perform serial CMR even after ICD placement [159]. Importantly, the optimal frequency of repeating scans as well as difficulty in interpretation of studies makes the precise role of radionuclide scans and frequency of tests controversial.

**Coronary angiography**

Coronary angiograms are often done in patients with suspected CS to exclude atherosclerotic coronary artery disease. Coronary angiograms are typically normal in CS, but wall motion abnormalities may be observed on ventriculograms [169]. Rarely, vascular filling defects due to granulomatous vasculitis [93] have been described.

**What is the role of endomyocardial biopsies?**

Transvenous right ventricular EMB have been used to diagnose CS, particularly when the multisystem disease is not evident [170,171], but sensitivity is low (19%-36%) [98,112,172,173]. The presence of granulomas on histologic samples confirms the diagnosis [67] (Figure 1E). Other histopathologic findings (e.g., myocardial interstitial fibrosis; heart muscle disarrangement and fragmentation; inflammatory mononuclear cell infiltrates) [67,98,171] may support the diagnosis of CS but are nonspecific. In two series of patients with *probable* CS, the yield of EMB was only 19% (5 of 26) [173] and 22% (4 of 18), respectively [172]. In a study of 52 patients with CS seen at one institution, EMB demonstrated CS in 10 of 31 (32%) patients at *initial* biopsy [98]. The diagnosis was established in seven additional patients by repeat EMB (targeted by cardiac imaging); in 11 patients, the diagnosis of CS was confirmed by sampling (+) mediastinal lymph nodes. Importantly, the diagnosis of CS was established in four patients after cardiac transplantation and in one at necropsy post SCD. Electrogram characteristics at the biopsy site may predict higher yield. Target sites with abnormal or low electrogram amplitude were associated with good sensitivity (67%) and specificity in a series of 11 EMB [174].

The low yield of EMB likely reflects sampling error. Cardiac sarcoidosis involves the myocardium in a patchy fashion, particularly in early or mild disease [9]. EMB are obtained mostly from the RV septal wall and apex of the VVS, but NNG more commonly are found in the LV free wall or base of the septum [9]. Although some authors have cited low risk of bleeding complications even with LV EMB [175], most centers rarely perform LV EMB given concern about bleeding given systemic LV pressures [176,177]. We do not recommend routine EMB to confirm myocardial involvement provided other objective measures of cardiac dysfunction or abnormality are substantiated (particularly by radionuclide techniques). As will be discussed later, radionuclide and CMR imaging are critical to narrow the diagnosis. In sarcoid patients with cardiac dysfunction, CHB or VA with no alternative etiology should be presumed to have CS, even when EMB are nondiagnostic.

**Differential diagnosis and mimics of cardiac sarcoidosis**

The differential diagnosis of CS is complex as the clinical signs (if present) and features on imaging studies overlap with other cardiac disorders. The differential diagnosis includes dilated cardiomyopathy (all causes) [68,176], arrhythmogenic right ventricular cardiomyopathy (ARVC) [178,179], idiopathic giant cell myocarditis (GCM) [180], lymphohcytic myocarditis, connective tissue disease [181], vasculitis (including Eosinophilic Granulomatosis with Polyangiitis [182,183] and Takayasu arteritis [184]), amyloidosis [185], dengue fever [186], Chagas disease [187] and other infectious causes (e.g., rheumatic fever, syphilis, fungal infections, tuberculosis). When the clinical presentation is isolated conduction system disease (1st, 2nd, or 3rd degree HB or BBB), the differential includes age-related conduction system disease, Lyme disease, Brugada syndrome, and myocarditis [178,188].

**Is there a role for routine screening for cardiac sarcoidosis?**

Mehta, et al. screened 62 ambulatory patients with sarcoidosis for possible cardiac involvement by ECG, Holter
monitoring, TTE, and cardiac symptoms (i.e., palpitations, syncope, or pre-syncope) [189]. Those with positive symptoms or screening tests underwent CMR and PET scans. Overall, 24 (39%) had CS. Not surprisingly, patients with CS had more cardiac symptoms than those without cardiac involvement (46% vs 5%, respectively; p < 0.001), and were more likely to have abnormal Holters (50% vs 3%, respectively; p < 0.001) and TTE (25% vs 5%, respectively; p = 0.02). Electrophysiological tests (EPS) were done in 17 patients, two of whom had abnormal findings and received an ICD. During almost 2-years of follow-up, no patients died or had VA that triggered ICD therapy or had heart failure [189]. These authors also evaluated a cohort of 76 patients with biopsy-proven systemic sarcoidosis without cardiac symptoms, but with evidence of CS by PET or CMR 190. All patients underwent programmed electric stimulation (PES) of the ventricle. Sustained VA was induced in eight (11%) subjects; all eight received an ICD. None of 68 non-inducible subjects received an ICD. All patients were followed for survival and arrhythmic events. Initial LVEF (by TTE) was lower in patients with inducible VA (36.4% vs 55.8%, p < 0.05). Over a median follow-up of 5 years, 6 of 8 patients in the group with inducible VA had further episodes of VA or died, compared with one death in the non-inducible group (p < 0.0001) [190]. Finnish investigators described nine patients in whom VA [VT or Ventricular Fibrillation (VF)] was the presenting feature of sarcoidosis; EMB were positive in eight [191]. All patients received Anti-Arrhythmic Agents (AAA) and ICDs; eight received high-dose steroids. During follow-up (50 +/- 34 months), five patients underwent appropriate ICD therapies and NSVT episodes were detected in four; two developed incessant VT, treated by catheter ablation. One patient was referred for heart transplant [191]. Dutch investigators recently performed a meta-analysis comprising 1,247 cases of CS over a period of 1.7 to 7 years and found that nine of 664 patients (1.36%) with CS without ICDs died suddenly [164]. Positive LGE-CMR and (+) Programmed Electric Stimulation (PES) were associated with a relative risk (RR) of 8.6 and 9.1 increased risk of VA, respectively [190]. Further, (+) LGE-CMR and (+) 18FDG-PET were associated with 6.82- and 3.41-fold increased risk of major ACE, respectively [164]. Since SCD [190,192] can occur even in asymptomatic patients with CS, an ICD should be placed in any patient with CS and a history of serious VA or inducible VT. The course of patients with CS and negative PES (non-inducible) appears more favorable, but additional studies are required to determine long-term prognosis and appropriate therapeutic management in this context.

Treatment of cardiac sarcoidosis

The prognosis of symptomatic CS is not well defined, but mortality rates of untreated CS are high 13,18,68,69. Numerous publications have cited favorable responses to corticosteroids (steroids) in patients with CS 2,68,169,193 but randomized trials have not been done. Nonetheless, steroids, alone or combined with additional Immunosuppressive Agents (IAs), remain the mainstay of treatment of CS 1.3.

Anti-arrhythmic Agents and Treatment of Heart Failure

Anti-Arrhythmic Agents (AAA), diuretics, and medications to treat HF have important adjunctive roles to treat CS and VAs. However, these agents do not eradicate the underlying cause (i.e., inflammation) and breakthroughs (including SCD) can occur even while on AAA [112,194,195]. Further, the predictive value of PES-induced VA and guided anti-arrhythmic medical therapy in CS is limited [190,196,197]. Serious (even fatal) VT can develop even in patients in whom VT could not be induced [72,196].

Cardiac ablation

Cardiac ablation may be efficacious in patients with persistent VT despite medical therapy [191,198–200]. In one study of 42 patients with CS, VT was not controlled despite medical therapy (steroids, AAA) and ICD in nine patients [198]. Radiofrequency ablation resulted in decreased (n=4) or complete (n=5) elimination of VT in all patients. Arrhythmic events decreased from a mean of 271 +/- 363 episodes pre-ablation to 4.0 +/- 9.7 post-ablation [198]. However, ablation is not consistently effective. Thachil, et al. reported 14 patients with sustained monomorphic VT (SMVT), mediastinal adenopathy, and abnormal PET in the mid-myocardium consistent with scar +/- inflammation [73]. Mediastinal lymph node biopsies revealed NNG in all 14 patients; 11 (79%) had tuberculosis (TB). All patients received AAA +/- radiofrequency ablation, yet SMVT recurred in 92%. The addition of disease-specific therapy (for TB or sarcoidosis) abolished further recurrences in 64%. The reduction/disappearance of SMVT correlated with resolution of myocardial inflammation on serial PET–CTs [73].

Implantable Cardioverter Defibrillators (ICDs)

Implantable cardioverter defibrillators (ICDs) are indicated for patients with CS with a history of VA or AVB, as medical therapy is not consistently effective. In one study, PES was performed in 32 consecutive patients with CS [72]. ICDs were placed in all 12 patients with spontaneous or inducible sustained VT; the other 20 did not receive ICD. All 32 patients were followed for the combined arrhythmic event end-point of appropriate ICD therapies or sudden death. The mean length of follow-up to sustained VA or sudden death was 32 +/- 30 months. Five of six patients with spontaneous sustained VA and four of six patients without spontaneous but with inducible sustained VA received appropriate ICD therapy. No patient with an ICD died of primary VA. Among patients with spontaneous or inducible sustained VA, mean survival from first appropriate ICD therapy to death or heart transplant was 60 +/- 46 months; only two of 12 patients with ICD died or required heart transplant at study end. Two of 20 patients (10%) with neither spontaneous nor inducible sustained VA who did not receive ICD experienced sustained VA or SCD [72].

Schuller, et al. reported 112 cases of CS who received ICDs for prevention of SCD [201]. Over a mean follow-up of 29.2 months, 36 (32.1%) received appropriate therapies for VT. VT storm (> 3 episodes in 24 hours) occurred in 16 (14.2%) CS subjects; 13 (11.6%) received inappropriate therapies. Variables associated with appropriate therapies include LVEF < 55% (OR 6.52), RV dysfunction (OR 6.73) and, symptomatic HF (OR 4.33) [201]. In patients with recurrent monomorphic VT, ICDs +/- catheter
ablation may have important roles [73] but do not eliminate the need for concomitant anti-inflammatory therapy with steroids or IAs. In one series, seven patients with CS had sustained VT; LVEF was < 45% in six [112]. All patients received AAA; five received shocks. Two patients had SCD and four had recurrent VT two or more months after initiation of steroid therapy [112].

Given the potential for serious VA and SCD, sarcoid patients with severe VA, advanced AVB, or cardiomyopathy should receive ICDs in addition to medical therapy [112,196,197,202-205]. Recommendations and Society Guidelines to treat VA in CS have been published [102,206]. Muhonen, et al. reported 33 cases of CS at the University of Louisville (USA) from 2002-2010, 30 of whom received ICDs [207]. Twelve patients (36.3%) had sustained VT; 11 received appropriate ICD therapies (36.7%) and nine received inappropriate shocks (30.0%). Patients who received appropriate ICD therapies were younger and had a lower mean LVEF compared to those who did not receive ICD therapies (p = 0.031 and 0.041, respectively) [207]. No other electrophysiological or imaging markers predicted the future occurrence of malignant VA. A multicenter study (13 sites) followed 235 patients who received ICDs for CS [208]. During a mean follow-up of 4.2 ± 4.0 years, 85 (36.2%) patients received appropriate ICD therapy (shocks and/or anti-tachycardia pacing) but 57 patients (24.3%) received 222 inappropriate shocks; further, 46 adverse events occurred in 41 patients (17.4%). Patients who received appropriate ICD therapies were more likely to be male (73.8% vs 59.6%, p = 0.033), have a history of syncope (40.5% vs 22.5%, p = 0.004), lower LVEF (38.1 vs 48.4%, p < 0.0001), ventricular pacing on baseline TTE (16.1 vs 21.0%, p < 0.0001) and a secondary prevention indicator (60.7 vs 24.5%, p < 0.0001) [208]. Takenaka, et al. reported 188 consecutive cases of CS in two tertiary Japanese hospitals between 1979 and 2020. During a median follow-up of 5.68 years, the primary outcome (i.e., VT/VF or SCD) was met in 44 (23%) patients [209]. LVEF > 35% or < 35% did not predict the incidence of the primary outcome [209]. These various studies show that patients with CS and AVs are at high risk for VA and SCD, and ICDs may be life-saving [72,112,164,201,207-209]. However, the rate of inappropriate shocks and device complications is not trivial [208].

Corticosteroid therapy for Cardiac Sarcoidosis

Corticosteroids are the mainstay of therapy for CS and have been associated with clinical improvement and lower mortality rates compared to no treatment, but randomized trials have not been done. In 2001, Yazali, et al. described 95 Japanese patients with CS seen between 1984 and 1996 [112]. The diagnosis of CS was made at necropsy in 20 cases, none of whom had been treated with steroids. All 75 in whom the diagnosis was established antemortem were treated with steroids. During a mean follow-up of 68 months, 29 of 75 treated patients (39%) died of HF and 11 (15%) died suddenly. Five-year survival rates (by Kaplan-Meier analysis) were 75% in the steroid-treated cases compared to only 10% in (untreated) autopsy cases. There were no significant differences in survival curves of patients treated with a high initial dose (> 30 mg) or a low initial dose (< 30 mg) of prednisone [18]. Another Japanese study of 195 cases of sarcoidosis treated with steroids cited a lower response rate to steroids (48%) among CS cases compared to > 70% response when sarcoidosis involved only non-cardiac sites [210]. The extent and severity of the disease may influence therapeutic responsiveness. Kato, et al. described 40 cases with CS, 20 of whom had AVB but normal cardiac function (LVEF > 50%) [193]. In the subset of 20 patients with normal LV function, seven were treated with steroids; 13 were not treated. During a mean observation period of 79.4 ± 39.9 months, none of seven treated patients died whereas two of 13 (15.4%) untreated patients died [193]. AVB resolved in four of seven steroid-treated patients but did not resolve in any of 13 untreated patients (p < 0.05). While LVEF did not differ significantly between the treated and untreated groups at the time of initial evaluation (66.7% vs. 60.5%), LVEF declined in the untreated cases during follow-up (LVEF 37.6 ± 17.3%), but not in the treated group (LVEF 62.1 ± 4.4%; p < 0.005) [193]. At the initial assessment, VT was not present in any patient in either group. During follow-up, VT occurred in only one of seven treated cases (14.3%) compared to eight of 13 untreated cases (61.5%; p < 0.05) [193]. In another study, 31 Japanese subjects with CS and frequent PVCs (> 300/day) were followed: 14 had NSVT [211]. All cases were treated with prednisone (initial dose 30 mg/day). There was no difference in the number of PVCs or incidence of NSVT before or after steroid therapy. However, in patients with LVEF > 35%, the number of PVCs per 24 hours declined from 1,820 to 742 and the prevalence of NSVT fell from 41% to 6%. Cases with LVEF > 35% had a significantly higher prevalence of cardiac Ga67 uptake compared to cases with LVEF < 35%. This suggests that steroids may be effective in the early inflammatory phase, but not in the late stages of CS [211]. These investigators subsequently reported 15 patients with CS advanced or complete AVB; all were treated with prednisone (initial dose 30 mg/day) after placement of an ICD [212]. During a mean follow-up of 7.1 years, AVB resolved to normal or 1st degree AVB in seven cases (47%). In the responder group, advanced AVB did not recur and LVEF was higher (69.4%) compared to non-responders (LVEF 44.1%) [212]. Nagai, et al. reported 83 consecutive cases of CS in Japan from 1990-2012 with a mean follow-up of 7.6 ± 4.4 years; 67 (81%) were treated with steroids; 2% received other IAs [24]. There were no differences in frequency of AVB, VT, or HF at the time of diagnosis in treated versus untreated cases. The mean initial daily dose of prednisone was 29.5 mg; the median duration of steroid therapy was 7.1 ± 4.4 years. Steroid therapy was associated with fewer hospitalizations for HF and an increase in LVEF at follow-up compared to untreated patients although there were no differences in cardiac deaths or symptomatic arrhythmias between groups [24]. In another study by these investigators, the impact of discontinuing steroids was evaluated in a cohort of 61 consecutive cases of CS treated with steroids and followed for a median of 9.9 years [25]. Steroids were discontinued in 12 patients following clinical improvement; none of the 12 who discontinued steroids were taking other IAs. After discontinuing steroids, LVEF fell and five of 12 (41.7%) died of cardiac causes; by contrast, cardiac death occurred in only six of 49 (12.2%) who continued steroid therapy. In summary, discontinuation of steroids was associated with increased cardiac mortality (p = 0.035) and greater decline in LVEF compared to continuation of steroids (p = 0.037) [25].

A retrospective study at Albany Medical Center (USA) (2001–2014) assessed the impact of “early” (within 30 days of diagnosis of CS) steroid therapy in a cohort of 30 cases of CS [5]. Steroid therapy was initiated in 27 cases (“early”), i.e., within 30 days of onset of symptoms in 23 cases) and “delayed” (i.e., > 30 days) in four cases; three were not treated. While the dosage of steroids varied, the “vast majority” received prednisone 30–40 mg daily for at least one month, followed by a gradual taper. ICDs were placed in 13/14 (93%) with VA. Clinical endpoints included mean LVEF, VA, and advanced (grade 2 or 3) AVB. At entry, 14 (47%) had LV systolic dysfunction; 14 (47%) had VA; five (17%) had advanced AVB. Among 14 cases who received “early” steroids, LVEF improved in nine (from the mean of 25% to 46%, p < 0.001). Among five receiving “delayed” or no steroid therapy, LVEF did not improve (41% to 37%, p = 0.47). Further, 8/11 (72%) with VA who received “early” steroids had no recurrence whereas all three with “delayed” steroids had recurrent VA. Advanced AVB resolved in two of three in the early steroid group and persisted in both patients receiving delayed steroids. Despite the small sample size, these data suggest that early treatment with steroids may improve clinical outcomes [5]. Japanese investigators retrospectively analyzed 15 CS patients with complete AVB treated with steroids [213]. An “early” diagnosis (within 1 year) was made in 10 cases; the diagnosis of CS was “late” (> 1 year) in five. Interestingly, extra–cardiac sarcoidosis was diagnosed in 60% of “early” and 0% in the “late” group (p = 0.044); further, TTE was abnormal in 70% of “early” and 0% in “late” cases (p = 0.0256). Importantly, after steroid therapy, LVEF and brain natriuretic peptide (BNP) significantly improved in the early compared to late group [213]. This supports the importance of early initiation of therapy to optimize outcomes. A recent update by these investigators reported 24 patients with CS and complete or advanced AVB receiving steroid therapy [214]. Univariate Cox analysis demonstrated that LVEF (HR 1.07, p = 0.016), the shorter interval from recognizing AVB to start of therapy (HR 0.98, < 0.001), and serum lysozyme levels (HR 1.51, p = 0.013) were significantly associated with resolution of AVB [214]. Sadek, et al. performed a meta–analysis of 10 publications that evaluated steroid treatment of CS [215]. There were no randomized trials and all publications were considered of “poor to fair quality”. Among 57 patients with AV conduction disease treated with steroids, 47.4% improved whereas none of 16 untreated patients improved [215].

Despite the lack of randomized trials, extensive clinical experience strongly supports aggressive treatment with steroids for clinically–evident CS [1,3,27,216]. However, data are too limited to comment on the dose or appropriate duration of steroid therapy and/or when to initiate IA (or which agent). In the following section, we discuss the role of IA (typically together with steroids) to treat CS.

**Therapy for CS: Role of Immunosuppressive Agents (IAs)**

Failures (including SCD) may occur in patients with CS despite high dose steroids [199,200]. IA has an important adjunctive role in CS, not only for steroid–sparking properties but may also enhance efficacy [29,30]. A variety of IA and Disease Modifying Anti–Rheumatic Agents (DMARA) have been used to treat pulmonary and extra–pulmonary sarcoidosis (including steroid–recalcitrant cases) [27,30,31,217–221]. Although randomized trials are lacking, methotrexate (MTX) has been the IA most often used to treat CS [26,222] and recommendations regarding its use have been promulgated by WASOG [26]. An international retrospective cohort study evaluated 200 sarcoidosis patients who had completed > one year of therapy with either MTX (n=145) or azathioprine (AZA) (n=55) [222]. Both agents had similar steroid–sparring effects and pulmonary function tests improved similarly in both treatment groups. There were more infections in the AZA group (14.6%) vs 18.1% in the MTX group, p = 0.01 but there were no differences in other adverse effects [222]. Experience with IA and DMARA to treat CS is limited to retrospective series with different agents, doses, and duration of therapy. Gallegos, et al. recently reviewed 23 publications comprising 480 cases of CS treated with a range of DMARA [29]. The most commonly used non–steroidal agents were MTX and infliximab (IFX). The use of DMARA was steroid–sparring, with a reduction in the maintenance steroid dose [29]. We discuss a few major studies of IA use in CS (usually in tandem with steroids) below.

In a retrospective French study, 39 patients with CS were treated with steroids (initial dose prednisone ~ 1 mg/kg/day); 13 also received another IA [27]. All had extra–cardiac involvement. The average duration of therapy was 43 months (range 6–168 months). During long–term follow–up (average 58 months), 87% improved, and 54% were presumed cured; no patient died suddenly. Two patients worsened, one of whom did not receive pharmacological therapy. During follow–up, nine patients relapsed. At the time of relapse, prednisone dose was < 10 mg/day in five patients; prednisone had been discontinued in three patients. All nine relapses were treated with steroids (alone, or combined with IA); six were cured and three showed clinical and laboratory improvement [27]. Data are insufficient to assess the impact of IA or efficacy of specific IA [27]. In a subsequent retrospective study, these investigators followed 59 cases of CS for a median of 60 months [28]. The median age at initial cardiac signs was 42 years. First–line therapy was steroids alone (n=24) or combined with IA (n=35). Overall, 47/59 (80%) recovered; 12 remained stable or worsened [28]. Recovery rates were not significantly different in those treated with steroids alone (75%) compared to steroids plus IA (83%). Five (9%) died during follow–up; two deaths were attributed to CS. Overall one– and 5–year survival rates were 98% and 92%, respectively 39. A retrospective study from the University of Cincinnati (USA) reported 73 cases of “probable or highly probable” CS (4) based upon 2014 criteria per WASOG [102] over a 6–year period. All had extra–cardiac involvement, most commonly lung (94.5%). Presenting features included: reduced LVEF (54.8%); VT (35.6%); advanced AVB (19.2%). Cases were initially treated with prednisone (30 mg/day) plus IAs (most commonly MTX (n=47), AZA (n=23); mycophenolate mofetil (MMF) (n=9); hydroxychloroquine (n=11); other (n =11). ICD’s were placed in 59%. Cases with persistent disease after 6 months of therapy were treated with additional cytotoxic agents or biological agents [e.g., IFX, rituximab (RITUX)] [4].
Cases were followed for a median of 8.8 years. Five- and 10-year survival rates were 95.5% and 93.4%, respectively. At follow-up, 10 (13.7%) either had heart transplant (n=3) or died (n=7) from sarcoidosis. Multivariate analysis found no association between the type of immunomodulatory therapy and survival. However, Cox regression analysis showed that age > 46 years and lack of implanted pacemaker or defibrillator were the only independent predictors of mortality [4]. Finnish investigators reported 110 adults with CS seen between 1998-2012 [23]. Steroids were given to 102 subjects; the eight untreated cases were diagnosed at necropsy or via cardiac explant at transplant. Additional IA used included: AZA (n=50); MTX (n=6); MMF (n=2); cyclosporine (n=2); IFX (n=1). LVEF was impaired (< 50%) in 65 patients at diagnosis (59%) and showed no overall change over 12 months of steroid therapy. During a median follow-up of 6.6 years, 10/102 (9.8%) died of cardiac causes; 11 (10.8%) underwent heart transplant; six (5.5%) died of non-cardiac causes. Kaplan Meier estimates for 1-, 5-, and 10-year survival were 97%, 90%, and 83%, respectively. Heart failure at presentation was associated with a 10-year transplant–free survival of only 52.5% (p = 0.0001). Among patients treated with steroids, transplant–free survival was similar among those receiving initial doses of prednisone of < 60 or > 60 mg daily (log rank p = 0.561) and did not differ from those receiving steroids within 6 months of the onset of symptoms compared to > 6 months (log rank p = 0.867). Data were inadequate to assess the impact of IA on outcomes [23]. A retrospective study from Paris (2012–2016) reported 36 cases of CS; 24 were treated with steroids alone and 12 received steroids plus an IA (AZA (n=5); MTX (n=5); cyclophosphamide (CYC) (n=2)) [44]. At a median follow-up of 3.6 years, 13 (36.1%) had a cardiac relapse [i.e., reduced LVEF (n=4); HB (n=2); atrial tachycardia (n=1); VT (n=1); SCD (n=1)]. Relapse rate was 45.8% in the steroid alone group versus 16.7% in steroids + IA (p = 0.048). These data support combination therapy with steroids + IA. Other IA (e.g., leflunomide [223,224] and MMF [225,226]) have been used with anecdotal successes in pulmonary and extra-pulmonary sarcoidosis in small trials. In one retrospective study in neurosarcoidosis comparing MTX with MMF, relapses were more common with MMF, and time to relapse was shorter with MMF compared to MTX [226]. Given the paucity of data, the optimal agent or agents to treat CS, and appropriate duration of therapy, have not been elucidated.

**Tumor Necrosis Factor alpha (TNF-α) antagonists**

TNF-α antagonists are considered third-line agents used to treat CS, usually in cases failing or experiencing adverse effects from steroids or IA [32,227]. Interestingly, early placebo-controlled randomized trials in non-sarcoid populations with Congestive Heart Failure (CHF) found that TNF-α antagonists showed no benefit [228,229] and one study suggested harm [228]. These trials were stopped due to lack of benefit (i.e., clinical status, death, or hospitalization for CHF) and a black box warning against TNF-α antagonists exists for patients with CHF. However, TNF-α is a key mediator of inflammation and granuloma formation in sarcoidosis [30], so there is a strong rationale to use TNF-α antagonists in cases of sarcoidosis failing standard therapy. Importantly, several non–randomized trials in pulmonary [230] and extra-pulmonary sarcoidosis refractory to steroids or IA reported favorable responses to TNF-α antagonists [particularly infliximab and adalimumab (ADA)] [32,227,231–233]. A six-center trial in the USA treated 66 cases with neurosarcoidosis with IFX; favorable clinical responses occurred in 77%, including complete recovery in 28.8% [232]. In a multicenter trial in France, 132 patients with sarcoidosis (multiple sites) refractory to standard therapy received anti-TNF-α therapy (IFX in 91%) [234]. Clinical responses (complete or partial) occurred in 64%, but adverse effects were common (52%) including infections in 36%. There was no difference in outcomes between anti-TNF-α therapy alone versus anti-TNF-α therapy combined with another IA [234]. Although data regarding the use of TNF-α antagonists in CS are limited, a multicenter retrospective study in the USA reported 38 cases of CS (mean age 49.9 years) treated with IFX (n=30) or ADA (n=8) [34]. Increased cardiac uptake of 18FDG was present in 86% pre anti-TNF-α therapy and resolved or improved in 73% post treatment. The daily dose of prednisone decreased from the time of initiation of TNF-α antagonists from 21.7 mg to 7.2 mg at 12 months and LVEF remained stable (45.0 to 47.0%, p = 0.10). Infections (some serious) occurred in eight patients (21%) [34]. In another study of 36 consecutive cases of CS refractory to standard therapy, IFX was associated with improvement in at least one of three outcome categories in 26 (67%) [32]. Of 16 patients with serial dysrhythmias, there was a trend to reduce VT from 32% at baseline to 22% at 6 months and 10% at 12 months (p = 0.07) [32]. Serial LVEF in 25 pts demonstrated no change from baseline (41%) to 6 months of therapy (42%) [32]. In a single center study in the Netherlands, 22 patients with CS received IFX between 2016–2019 (dose 5 mg/kg at week 0, 2, and subsequently every 4 weeks) [33]. At a mean follow-up of 18.9 months (6 to 44 months), 18/22 (82%) had responded and median SUVmax on 18FDG-PET decreased (improved) from 5.2 to 2.3 (p = 0.015). None had worsening HF. No serious side effects were noted [33]. Rosenthal, et al. reported 28 cases of CS followed for a mean of 4.1 years [231]. Following initial treatment with steroids and MTX, 19 patients with persistently active CS or intolerance to MTX received ADA. Adalimumab was associated with improvement (84%) or resolution (65%) of 18FDG uptake [231]. Data regarding other TNF-α antagonists are limited. However, etanercept was ineffective as therapy for progressive pulmonary sarcoidosis [235] or chronic ocular sarcoidosis [236]. Further, etanercept has a higher incidence of paradoxical sarcoid-like reactions compared to other TNF-α antagonists [240,241]. These data are interesting, but data are extremely limited and these agents should be considered experimental or for consideration only when failing other existing therapies. Similarly, the role of inhibitors to certain cytokines and chemokines such as interleukin (IL)–6, IL12, IL17 [30] and...
others are worthy of future consideration but will not be further discussed in this review.

Our approach to the treatment of cardiac sarcoidosis

Given the complexity of CS, and possible SCD due to AV or CHB, a multidisciplinary approach including experienced cardiac electrophysiologists, experts in cardiomyopathy, and experts in sarcoidosis and immunosuppressive therapy is critical. Cardiologists manage HF, fluid status, arrhythmias, need for ICD or AAA, etc. while pulmonologists with expertise in CS and IA manage the steroid and immunosuppressive therapy. Appropriate use of diuretics and agents to treat HF and arrhythmias are important but do not eliminate the need for anti-inflammatory therapy with steroids +/- IA. Our therapeutic anti-inflammatory approach in patients with proven or suspected myocardial sarcoidosis is based in large part upon extensive clinical experience by one of us (JPL) in sarcoidosis (both cardiac and non-cardiac) [95,242–245] as well as expertise in immunosuppressive agents for inflammatory systemic disorders (including but not limited to sarcoidosis) [246,247]. Despite the lack of randomized trials, the evidence that steroids (with or without IA) have been associated with clinical responses and fewer ACEs in CS compared to no treatment is readily apparent. Further, discontinuing therapy after a favorable response can be dangerous, as relapses (even fatalities) may occur. For a patient with active or presumed active CS, we initiate treatment with steroids. Symptomatic patients or those with serious VA or HF typically receive a 3-day pulse of intravenous methylprednisolone (500–1,000 mg daily), followed by prednisone 40 mg/day for a minimum of 4 weeks. Patients without severe VA or HF are usually treated with prednisone alone for the first several weeks. After 4–6 weeks, we add an IA [most often MTX (15–25 mg once weekly) or AZA (100–150 mg daily)]. Prednisone is usually tapered to 30 mg after 4 weeks, and gradually to a maintenance dose of 10 mg by 6 months. The rate of CS taper is variable depending upon the clinical status and the presence or absence of adverse effects. The duration of therapy depends upon the individual case, but we typically maintain low dose prednisone (5–10 mg daily) with an IA for a minimum of 2–3 years since relapses can be life-threatening and may cause permanent damage. Clinical relapses of CS require re-treatment with high dose steroids and/or IA.

For follow-up, serial TTE (to assess cardiac function and LVEF) and BNP are done no less often than every 3 months. Interrogation of pacemakers every 3 months is recommended for patients with ICDs. The value of serial radionuclide studies “routinely” after six months is not clear, although we believe PET and/or CMR may be invaluable in cases with persistent or worsening symptoms.

Surgical options

Surgical resection of ventricular aneurysms may be necessary for the management of refractory VT [248–250]. Massive or recurrent pericardial effusions refractory to medical therapy may require pericardiectomy or pericardial window [69,85].

Cardiac transplantation

Cardiac transplantation should be considered for patients with severe intractable heart failure refractory to therapy [251–258]. In a review of 19 patients with CS who had a cardiac transplant, the five-year post-transplant survival rate was 79%, comparable to 83% five-year survival among recipients transplanted for other indications [251]. No patient had recurrent sarcoidosis in the cardiac allograft. Zaidi, et al. examined outcomes of 65 heart transplant recipients with CS from 1987 to 2005 in the USA national United Network for Organ Sharing (UNOS) database [253]. In that study, one- and five-year survival rates were 87.7% and 80.5% compared to 84.5% and 70% survival among heart transplant recipients without sarcoidosis [253]. A recent meta-analysis cited similar one- and five-year survival rates post heart transplant for CS compared to other etiologies, although survival rates were statistically better in patients with CS after 5 years [259]. Rosenthal, et al. reported 12 patients with CS who received heart transplants and 28 heart transplant recipients without sarcoidosis; lung allograft rejection was less common in the CS group (17% vs 68%, p = 0.006). None of the 12 sarcoid patients died or developed recurrent CS [260]. Recurrent sarcoidosis has been described in cardiac allografts [256,261–264], but is uncommon (< 10%) [251,252,259] and may respond to intensification of corticosteroids [265].

Summary and key points (Table I)

- The diagnosis of CS may be difficult, as endomyocardial biopsies are positive in < 40% of cases.
- A probable diagnosis of CS can be made when characteristic clinical features [e.g., arrhythmias (especially VA), AVB, or cardiomyopathy are present, together with histologically confirmed sarcoidosis in other organs]
- Radionuclide scans (PET and CMR) are important to support the diagnosis and in some cases may be useful to assess resolution or relapse of disease but appropriate monitoring remains controversial.
- Treatment requires a multidisciplinary team including cardiologists with expertise in arrhythmias, heart failure, and cardiomyopathy, as well as individuals with extensive experience in sarcoidosis and the use of immunosuppressive agents.
- Therapy for specific cardiac events (arrhythmias, cardiac failure) is critical, but are insufficient since those therapies do not influence granulomatous inflammation, the driver of the cardiac manifestations.
- Implantable cardioverters and defibrillators (ICDs) should be placed in any patient with CS with severe VA, heart block, or severe heart failure and may be lifesaving.
- Although randomized, placebo-controlled trials have not been done, extensive clinical studies have shown...
Table 1: Diagnosis of Cardiac Sarcoidosis.

**Histological Diagnosis**
- Myocardial biopsy showing non-necrotizing granuloma with negative stains and smears for other etiologies (mainly infectious). **Highly specific but sensitivity low (17-36%).**
- Extra-cardiac biopsy showing non-necrotizing granulomas (particularly in lung, mediastinal and hilar lymph nodes) with alternative etiologies (particularly infections) excluded. Supports but does not confirm the diagnosis of cardiac sarcoidosis.

**Clinical features (common but nonspecific)**
- Unexplained arrhythmias (particularly ventricular tachycardia and/or ventricular fibrillation but also atrial arrhythmias)
- Unexplained atrioventricular block (particularly Mobitz type 2 or 3rd degree)
- Younger age (< 65 years); absence of coronary artery disease

**Laboratory features:**
- Transthoracic echocardiogram: Regional abnormal wall motion abnormalities, global or focal hypokinesia or dyskinesia, chamber enlargement, ventricular dilatation or hypertrophy, ventricular wall thickening or thinning, depressed ejection fraction. Common but completely nonspecific.
- Serum angiotensin converting enzyme levels (low sensitivity since SACE correlates with total body granuloma burden and is usually not elevated in CS).

**Radiographic features**
- High resolution computed tomographic (HRCT) scan: Pulmonary micronodules, peribronchiolar and upper lung field predominance, with or without reticular alveolar opacities may support the diagnosis of sarcoidosis. In this context, transbronchial lung or mediastinal lymph node biopsies may reveal NNG.

**Radionuclide scans**
- Gallium-67-citrate and thallium-201 scans: Perfusion defects that improve or resolve with exercise or dipyridamole (moderately sensitive, but these scans are primarily of historical interest and have been replaced by PET and CMR scans).
- Fluorodeoxyglucose (FDG) positron emission tomography (PET) scans: Increased FDG-avidity in myocardium (diffuse, focal, or focal on diffuse) +/- perfusion defects or wall motion abnormalities. Extracardiac foci of FDG-avidity in lung, mediastinal or hilar lymph nodes or other sites support the diagnosis of sarcoidosis. Changes in FDG avidity may reflect increases or decreases in inflammation.

**Gadolinium cardiac magnetic resonance (MRI):** Late (delayed) enhancement of gadolinium in myocardium not in distribution of prior myocardial infarction. Sites of activity may be patchy or focal with the most common affected areas being LV free wall, interventricular septum, and/or papillary valves. May have increased signal intensity in T1 and T2-weighted images.

Benefits with corticosteroid therapy, either alone or with other anti-inflammatory agents (particular immunosuppressive agents).
- Dual drug therapy (with steroids and an IA) is logical, given the steroid-sparing effects of IA as well as enhanced efficacy in some cases.
- Duration of therapy has not been well established, although long-term (> 2–3 years, possibly indefinite therapy) may be required.
- Heart transplantation is an option for CS cases with severe intractable heart failure or arrhythmias despite medical therapy, with results comparable or better than non-sarcoid cases.

**References**


Link: https://bit.ly/3y48SUJ

Link: https://bit.ly/3lM03Ae

Link: https://bit.ly/3pHL17j

Link: https://bit.ly/3DBDJPZ

Link: https://bit.ly/3s1B53Z

Link: https://bit.ly/3HINAmK

Link: https://bit.ly/308lDD0

Link: https://bit.ly/3ECRHCv

Link: https://bit.ly/3rNb1cG

Link: https://bit.ly/3IG6D0b

Link: https://bit.ly/3oWwYc

Link: https://bit.ly/3lFNaka


Link: https://bit.ly/3EFHryh

Link: https://bit.ly/3dXuhh


Link: https://bit.ly/3DGXISU

Link: https://bit.ly/3hICZX

Link: https://bit.ly/30nznxFd

Link: https://bit.ly/3dyirbb

Link: https://bit.ly/3m6zPJ5

Link: https://bit.ly/3y7k21h

Link: https://bit.ly/3dvWNk

Link: https://bit.ly/3EB09H

DOI: https://dx.doi.org/10.17352/2455-2976.000175


---


Discover a bigger impact and visibility of your article with Peertechz Publications

**Highlights**
- Signatory publisher of ORCID
- Signatory publisher of DORA (San Francisco Declaration on Research Assessment)
- Articles archived in world's renowned service providers such as Portico, CNKI, AGRIS, TDNet, Base (Bielefeld University Library), CrossRef, Scilit, J-Gate etc.
- Journals indexed in JCI, ESI, I-ISSNP, OCLC, Google Scholar etc.
- OA/OA (Open Access Initiative Protocol for Metadata Harvesting)
- Dedicated Editorial Board for every journal
- Accurate and rapid peer review process
- Increased citations of published articles through promotions
- Reduced timeline for article publication

Submit your articles and experience a new surge in publication services (https://www.peertechz.com/submission).

Peertechz journals wishes everlasting success in your every endeavour.